Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Heart Failure, Pulmonary Hypertension, P...
Phase Not Applicable
Enrollment 230
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Heart failure (HF) patients often develop pulmonary hypertension (PH) that leads to transition into a biventricular HF with poor prognosis. There are two PH components: 1) passive transmission of increased left atrial pressure, 2) heart failure (HF) related pulmonary vascular dysfunction (PVD) with increased vascular resistance. Intriguingly, only some, but not all HF patients develop heart failure-related PVD. The mechanisms and non-invasive detection of HF-PVD are poorly understood and are the focus of the current grant application. Development of PVD is linked to insufficiently characterized metabolic factors that may be mediators of HF-PVD. Untargeted metabolomics is an emerging powerful platform for the discovery of pathways linked to diseases. Its specificity can be further enhanced using transpulmonary gradient sampling. Part A of the project aims to identify novel metabolites associated with the presence of PVD in patients with HF that can serve as biomarkers or targets and will provide biologic insights into PVD. Part C will assess the effects of reverting of metabolic alterations (identified in part A) by a drug/diet on pulmonary vasculature in experimental HF-related PVD. The "gold standard" for the detection of PVD is right heart catheterization, which is invasive and risky. Heart failure-related PVD is therefore often diagnosed late. There is a need for noninvasive tests that may help to detect PVD in early stages and can be done repeatedly. Recent advances in artificial intelligence (AI)-assisted automated quantitative analysis of lung texture from low-dose contrast-free high-resolution CT images allow to quantify lung water content, interstitial changes or vessel volume, and may provide clues for detection of heart failure-related PVD. Such an approach, not tested yet, will be utilized for the detection of HF-PVD (part B). Clinical and functional characteristics of lung circulation (exercise hemodynamics, diffusion capacity, perfusion) will be analyzed in relation to quantitative CT data.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: non-contrast chest CT — patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
  • Diagnostic Test: spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis — patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
  • Diagnostic Test: Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood — patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
  • Diagnostic Test: supine bike exercise during right heart catheterisation — subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC
  • Diagnostic Test: Lung ventilation/perfusion SPECT — subgroup of HF subjects will undergo ventilation/perfusion SPECT

Primary Outcomes

  • biomarker of pulmonary vasculopathy in HF (after recruitment and cross-sectional analysis of all enrolled subjects (no later than december 2026-the end of study))
  • CT characteristics of pulmonary vasculopathy in HF (after recruitment and cross-sectional analysis of all enrolled subjects (no later than december 2026-the end of study))
  • CT characteristics of presence of heart failure (after recruitment and cross-sectional analysis of all enrolled subjects (no later than december 2026-the end of study))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-08-23
Completion: 2026-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 230 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute for Clinical and Experimental Medicine
Principal Investigators:
  • Vojtech Melenovsky (PRINCIPAL_INVESTIGATOR) - Institute for Clinical and Experimental Medicine
Contact Information
Study Contact:
Vojtech Melenovsky, MD, PhD
420 236055190
vome@ikem.cz
Vojtech Melenovsky, MD, PhD
420 236055190
vome@ikem.cz
Institute for Clinical and Experimental Medicine - IKEM
Interventions
  • Diagnostic Test: non-contrast chest CT — patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
  • Diagnostic Test: spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis — patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
  • Diagnostic Test: Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood — patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
  • Diagnostic Test: supine bike exercise during right heart catheterisation — subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC
  • Diagnostic Test: Lung ventilation/perfusion SPECT — subgroup of HF subjects will undergo ventilation/perfusion SPECT
Study Locations (1 sites)
Institute for Clinical and Experimental Medicine - IKEM, Prague, 140 21 Czechia
Eligibility Criteria
A) Inclusion Criteria HF group: * age\>18y * signed informed consent, * left ventricular (LV) ejection fraction \<50% * duration of HF\>6 months, * loop diuretic use, * clinical indication to right heart catheterisation Control group: * Age \>18years * Signed informed consent * Non-HF subjects referred to Institute for Clinical and Experimental Medicine (IKEM) in Prague for an invasive procedure (PFO closure, arrhythmia ablation, for subjects undergoing RHC) or non-invasive diagnostic evaluation (controls without invasive sampling) B) Exclusion Criteria: Heart Failure group: * Patients with hemodynamic instability requiring inotropic support * Severe renal insufficiency (estimated glomerular filtration rate \<0.6 ml/s) * Acute coronary syndrome * High cardiac output (cardiac index \>4 l/m2) * Known pulmonary hypertension of other type than II (type I, III, IV) * Active infection * Respiration insufficiency * Large pleural effusion * Severe intrinsic lung disease (treated chronic obstructive pulmonary disease (COPD) * asthma, known interstitial lung disease) Control group: * Pulmonary hypertension (RV systolic pressure estimate on screening \> 45 mmHg) * History of recent pulmonary embolism \< 1 year * Echocardiographic evidence of reduced function of right or left ventricle * Treated asthma/COPD, known intersticial lung disease * Significant exercise intolerance (NYHA \> II)
Conditions Hypertension, Coronary Arterial Disease,...
Phase NA
Enrollment 207
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This prospective randomized open-label study aims to compare the effectiveness of two dual antihypertensive therapy regimens in patients with arterial hypertension and coronary artery disease after elective percutaneous coronary intervention (PCI) with coronary artery stenting. Patients requiring dual antihypertensive therapy will be randomized to receive either an angiotensin receptor blocker (ARB) combined with a thiazide diuretic or an ARB combined with a dihydropyridine calcium channel blocker. The study will evaluate blood pressure control, angina symptoms, quality of life, need for treatment intensification, and healthcare utilization during follow-up. Clinical status will be assessed at discharge and during telemedicine follow-up visits at 2 weeks, 4 weeks, and 12 weeks after hospital discharge. The primary endpoint is the percentage reduction in systolic and diastolic blood pressure. Secondary endpoints include frequency of angina episodes, exercise limitations, patient satisfaction with treatment, and medical consultations during follow-up. The study is investigator-initiated and plans to enroll at least 207 participants.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Losartan + Hydrochlorothiazide — Dual antihypertensive therapy consisting of an angiotensin receptor blocker combined with a thiazide diuretic administered after elective percutaneous coronary intervention.
  • Drug: Amlodipine + Azilsartan — Dual antihypertensive therapy consisting of an angiotensin receptor blocker combined with a dihydropyridine calcium channel blocker administered after elective percutaneous coronary intervention.

Primary Outcomes

  • Change in office systolic and diastolic blood pressure (mmHg) (2 weeks, 4 weeks, and 12 weeks after hospital discharge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2026-09
Eligibility
Age: 50 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 207 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Medical Research Center for Therapy and Preventive Medicine
Principal Investigators:
  • Olga Dzhioeva (STUDY_CHAIR) - National Medical Research Center for Therapy and Preventive Medicine
  • Oxana Drapkina (PRINCIPAL_INVESTIGATOR) - National Medical Research Center for Therapy and Preventive Medicine
Contact Information
Study Contact:
Elizaveta Rogozhkina
+7 (937) 104-73-31
lizarogozkina@gmail.com
Oksana Drapkina
+7 (495) 212-07-13
drapkina@bk.ru
National Medical Research Center for Therapy and Preventive Medicine
Interventions
  • Drug: Losartan + Hydrochlorothiazide — Dual antihypertensive therapy consisting of an angiotensin receptor blocker combined with a thiazide diuretic administered after elective percutaneous coronary intervention.
  • Drug: Amlodipine + Azilsartan — Dual antihypertensive therapy consisting of an angiotensin receptor blocker combined with a dihydropyridine calcium channel blocker administered after elective percutaneous coronary intervention.
Study Locations (1 sites)
National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
Eligibility Criteria
Inclusion Criteria: * Age 50 to 70 years * Arterial hypertension * Coronary artery disease * Hospitalization for elective percutaneous coronary intervention * Coronary artery stenting during the current hospitalization * Requirement for dual antihypertensive therapy * Treatment with beta-blockers, lipid-lowering therapy, and antiplatelet therapy * Ability and willingness to provide written informed consent Exclusion Criteria: * Refusal or inability to provide informed consent * Acute coronary syndrome * Active malignancy * Pulmonary embolism * Chronic kidney disease stage 4-5 * Type 2 diabetes mellitus * Contraindications or intolerance to study medications, including bilateral renal artery stenosis, hyperkalemia, hyperuricemia, or gout * Women of reproductive age * Permanent or persistent atrial fibrillation * Planned staged coronary stenting * Heart failure with reduced ejection fraction * Any other condition that, in the investigator's opinion, may interfere with participation in the study or interpretation of study results
Conditions Essential Hypertension, Healthy Voluntee...
Phase PHASE1
Enrollment 46
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose phase 1 clinical study, aimed at evaluating the safety, tolerability, PK, PD and immunogenicity of single subcutaneous administration of MWX401 Injection in healthy Chinese participants and participants with primary mild hypertension. The study comprises five dose cohorts with a planned enrollment of 46 subjects. The primary endpoint is the incidence and severity of treatment-emergent adverse events. Secondary endpoints include plasma and urinary PK parameters, changes in serum AGT and RAAS components, changes in blood pressure and hemodynamics, and immunogenicity indicators.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: MWX401 1 — Administered subcutaneously (SC)
  • Drug: MWX401 2 — Administered SC
  • Drug: MWX401 3 — Administered SC
  • Drug: MWX401 4 — Administered SC
  • Drug: MWX401 5 — Administered SC
  • Drug: Placebo — Administered SC

Primary Outcomes

  • Incidence and severity of treatment-emergent adverse events (TEAEs) (Through study completion, for at least 85 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-03-19
Completion: 2026-12
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: true
Enrollment: 46 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Minwei Biotechnology Co., Ltd
Contact Information
Study Contact:
Wanxiang Chen
+86 13359015677
chenwanxiang@minweibiotech.com
Yuwen Su, Doctor
+86 13776688046
13776688046@163.com
The Affiliated Sir Run Run Hospital, Nanjing Medical University
Interventions
  • Drug: MWX401 1 — Administered subcutaneously (SC)
  • Drug: MWX401 2 — Administered SC
  • Drug: MWX401 3 — Administered SC
  • Drug: MWX401 4 — Administered SC
  • Drug: MWX401 5 — Administered SC
Study Locations (1 sites)
The Affiliated Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu China
Eligibility Criteria
Inclusion Criteria: 1. Male or female participants aged 18 to 60 years (inclusive) at the time of signing the informed consent form (ICF). 2. Body mass index (BMI) within 19.0 to 30.0 kg/m\^2 (inclusive) at screening, with body weight \>= 50 kg. 3. No use of antihypertensive medications within 30 days prior to signing the ICF, including beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), angiotensin receptor-neprilysin inhibitors (ARNIs), and diuretics. 4. At screening and baseline, average seated office blood pressure: healthy participants: SBP 120-139 mmHg (inclusive) and DBP 75-89 mmHg (inclusive); participants with mild hypertension: SBP 140-159 mmHg (inclusive) and DBP 90-99 mmHg (inclusive). 5.12-lead electrocardiogram results normal or judged by the investigator as abnormal without clinical significance, with QTcF (Fridericia's formula) \< 450 ms (male) or \< 470 ms (female). 6\. Voluntarily sign the ICF before any study-related procedure, able to understand and willing to comply with the requirements of the study protocol. Exclusion Criteria: 1. History or evidence of secondary hypertension, including renal parenchymal hypertension, renovascular hypertension, aortic stenosis, primary aldosteronism, Cushing's syndrome, pheochromocytoma, polycystic kidney disease, drug-induced hypertension, etc. 2. History of type 1 or type 2 diabetes mellitus. 3. Pulse/heart rate \<55 bpm or \>100 bpm at screening. 4. eGFR (CKD-EPI) \<80 mL/min/1.73 m² at screening. 5. Body weight loss \>5% within 6 months before screening, or planned weight loss during study. 6. History of or current orthostatic hypotension (SBP drop ≥20 mmHg or DBP drop ≥10 mmHg within 1 min of standing from supine). 7. History of syncope before screening. 8. Use of prescription drugs, herbal products, or dietary supplements that may affect safety or data integrity within 30 days before randomization. 9. Excessive blood pressure fluctuation (SBP fluctuation \>20 mmHg during screening). 10. History of needle phobia, difficult blood sampling, or intolerance to venipuncture. 11. Any other condition deemed unsuitable for study by investigator.
Conditions Hypertension
Phase NA
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Hypertension (HT) is an important risk factor for cardiovascular diseases (CVD) and death. Approximately 16.9 million people in Turkey have HT. Nutritional habits play an important role in the development of HT. DASH (Dietary Approaches to Stop Hypertension) and the Mediterranean diet (MD) have been found to be effective in lowering blood pressure and reducing cardiometabolic risks. The DASH diet stands out with its low sodium, saturated fat, simple sugar and cholesterol content, while it is rich in fiber, potassium, magnesium and anti-inflammatory components. The MD is based on healthy foods such as olive oil, vegetables, fruits, fish and nuts, and contains antioxidants and healthy fatty acids. This study will investigate whether the sodium-restricted MD can offer a model comparable to DASH. In addition, the effects of the intermittent fasting diet (IFD) model alone and in combination with the MD on blood pressure will be examined. It has been observed that IFD reduces blood pressure by reducing energy intake and acting on the autonomic nervous system. The aim of this project is to evaluate the effects of MD, IFD and both of them on hypertension and to present a new and original approach in this field.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Face-to-face nutrition education — All participants will receive face-to-face nutrition education from specialist dietitians in accordance with the principles of nutrition for hypertension. Nutrition education will be provided through prepared brochures. The brochures will be given to participants as gifts. Nutrition education will cover topics such as hypertension and nutrition, nutrients, the importance of micronutrients, foods containing salt, reading labels, limiting salt consumption, healthy fat consumption, fibre consumption, water consumption, and healthy cooking methods.
  • Other: Intermittent Fasting Diet — Training will be provided to all participants through a food and nutrition photo catalogue so that portions can be recorded correctly and within standard limits when keeping a food diary. Participants will restrict their food intake to a 16-hour period by applying the 16/8 Intermittent Fasting Diet model and will eat and drink whatever they want during the remaining 8 hours. During this 16-hour period, they will consume non-energy drinks consisting of water, unsweetened tea, unsweetened herbal teas and black coffee. It will be recommended that intermittent fasting be maintained from 6:00 p.m. to 10:00 a.m. However, participants may also choose other 16-hour periods, such as 7:00 p.m. to 11:00 a.m. or 8:00 p.m. to 12:00 p.m. Participants will be given a tracking chart to record the first and last times they consume food or energy-containing beverages during the day, and their adherence to the diet will be monitored based on their declarations.
  • Other: Mediterranean Diet — Training will be provided to all participants through a food and nutrition photo catalogue to ensure that portions are recorded correctly and within standard limits when keeping a food diary. In addition, the dietician will provide this group with a diet plan calculated for energy, macro and micro nutrients, which will be different each week for the first four follow-ups. The diet plans provided will be prepared in accordance with the Mediterranean Diet food pyramid. Participants' energy requirements will be calculated using the Schofield Equation for basal metabolic rate, with adjustments made according to their physical activity levels. Energy requirements will be met by 45-50% from carbohydrates, 15-20% from protein, and 25-35% from fats.

Primary Outcomes

  • Blood pressure (At enrollment, 1 week later than enrollment, 2 weeks later than enrollment, 3 weeks later than enrollment, 4 weeks later than enrollment, 13 weeks later than enrollment, 26 weeks later than enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-13
Completion: 2027-01-15
Eligibility
Age: 40 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nadide Gizem Tarakci Filiz
Collaborators: Medipol University, Istanbul Medipol University Hospital, Fenerbahce University
Principal Investigators:
  • Mehmet KOÇAK, PhD (PRINCIPAL_INVESTIGATOR) - İstanbul Medipol Üniversitesi/Sağlık Bilim Ve Teknolojileri Araştırma Enstitüsü
Contact Information
Study Contact:
Mehmet KOÇAK, PhD
+90 530 097 75 33
mehmetkocak@medipol.edu.tr
Rüken Aslınur SAMANCI, MSc
+90 543 939 15 94
rasamanci@medipol.edu.tr
Aysel AKHUNDOVA, Dr.
+90 541 858 62 01
aysel.akhundova@medipol.edu.tr
Medipol Mega University Hospital
Interventions
  • Other: Face-to-face nutrition education — All participants will receive face-to-face nutrition education from specialist dietitians in accordance with the principles of nutrition for hypertension. Nutrition education will be provided through prepared brochures. The brochures will be given to participants as gifts. Nutrition education will cover topics such as hypertension and nutrition, nutrients, the importance of micronutrients, foods containing salt, reading labels, limiting salt consumption, healthy fat consumption, fibre consumption, water consumption, and healthy cooking methods.
  • Other: Intermittent Fasting Diet — Training will be provided to all participants through a food and nutrition photo catalogue so that portions can be recorded correctly and within standard limits when keeping a food diary. Participants will restrict their food intake to a 16-hour period by applying the 16/8 Intermittent Fasting Diet model and will eat and drink whatever they want during the remaining 8 hours. During this 16-hour period, they will consume non-energy drinks consisting of water, unsweetened tea, unsweetened herbal teas and black coffee. It will be recommended that intermittent fasting be maintained from 6:00 p.m. to 10:00 a.m. However, participants may also choose other 16-hour periods, such as 7:00 p.m. to 11:00 a.m. or 8:00 p.m. to 12:00 p.m. Participants will be given a tracking chart to record the first and last times they consume food or energy-containing beverages during the day, and their adherence to the diet will be monitored based on their declarations.
  • Other: Mediterranean Diet — Training will be provided to all participants through a food and nutrition photo catalogue to ensure that portions are recorded correctly and within standard limits when keeping a food diary. In addition, the dietician will provide this group with a diet plan calculated for energy, macro and micro nutrients, which will be different each week for the first four follow-ups. The diet plans provided will be prepared in accordance with the Mediterranean Diet food pyramid. Participants' energy requirements will be calculated using the Schofield Equation for basal metabolic rate, with adjustments made according to their physical activity levels. Energy requirements will be met by 45-50% from carbohydrates, 15-20% from protein, and 25-35% from fats.
Study Locations (1 sites)
Medipol Mega University Hospital, Istanbul, 34214 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed hypertension patients * Individuals with blood pressure \>140/90 mmHg * Individuals with a body mass index (BMI) in the range of 18.5-25 kg/m² * Individuals aged 40-65 years Exclusion Criteria: Participants will be excluded if they have any of the following: * Type 2 Diabetes Mellitus * Type 1 Diabetes Mellitus * Cardiovascular disease * Liver disease * Kidney disease * Gastrointestinal disease * Respiratory disease * Psychiatric disorders * Women who are pregnant or breastfeeding * Severe food allergies * Current smokers or individuals consuming alcohol regularly * History of major surgery within the last 6 months
Conditions Obstructive Sleep Apnea, Hypertension
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate the relationship between hypertension and obstructive sleep apnea (OSA) using heart rate variability (HRV) as a non-invasive biomarker of autonomic nervous system function. Hypertensive patients at high risk for OSA will undergo 24-hour Holter electrocardiogram monitoring to assess HRV parameters, along with overnight polysomnography (PSG) to determine OSA severity. The study will analyze the association between HRV indices and the apnea-hypopnea index (AHI), and develop predictive models using machine learning techniques. In addition, patients diagnosed with OSA will be followed after treatment, and changes in HRV and blood pressure will be evaluated to assess treatment effects and autonomic function recovery. The results of this study may provide a cost-effective and clinically applicable approach for early detection, risk stratification, and management of OSA in patients with hypertension.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Polysomnography — Overnight polysomnography (PSG) will be performed to evaluate sleep parameters and determine the severity of obstructive sleep apnea.

Primary Outcomes

  • Prediction of OSA Severity Using Heart Rate Variability (Baseline (at time of HRV monitoring and polysomnography))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-04-30
Completion: 2026-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kaohsiung Armed Forces General Hospital
Principal Investigators:
  • Yung Kuo Lee, PhD (PRINCIPAL_INVESTIGATOR) - Kaohsiung Armed Forces General Hospital
Contact Information
Study Contact:
Yung Kuo Lee, PhD
+886910977485
abstyle0204@gmail.com
Chih-Hsuan Chang, MS
+886905163699
abstyle0204@gmail.com
Yung Kuo Lee, PhD
+886910977485
yungkuolee@gmail.com
Kaohsiung Armed Forces General Hospital
Interventions
  • Diagnostic Test: Polysomnography — Overnight polysomnography (PSG) will be performed to evaluate sleep parameters and determine the severity of obstructive sleep apnea.
Study Locations (1 sites)
Kaohsiung Armed Forces General Hospital, Kaohsiung City, Kaohsiung Taiwan
Eligibility Criteria
Inclusion Criteria: * Age 18 to 65 years * Diagnosed hypertension or resistant hypertension * STOP-Bang score ≥3 indicating high risk of obstructive sleep apnea * Willing and able to provide informed consent Exclusion Criteria: * Refusal to undergo HRV monitoring or polysomnography * Unstable medical condition that may interfere with study participation * Inability to comply with study procedures
Conditions Primary Open Angle Glaucoma
Phase NA
Enrollment 86
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

A multicenter, randomized, clinical trial to evaluate the efficacy of canaloplasty performed as a standalone procedure using the iTrack™ Advance canaloplasty device (Nova Eye, Inc.) as compared to the OMNI® Surgical System (Sight Sciences) in patients with mild to moderate primary open-angle glaucoma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Ab-interno canaloplasty utilizing the iTrack Advance device — 360 degree microcatheterization and viscodilation of Schlemm's canal
  • Device: Ab-interno canaloplasty utilizing the OMNI Surgical System — 360 degree microcatheterization and viscodilation of Schlemm's canal

Primary Outcomes

  • The mean change in unmedicated Intraocular pressure (IOP) at Month-12 compared to baseline (12 months)
  • Percentage of eyes achieving a 20% or greater reduction in unmedicated Intraocular pressure (IOP) at Month-12 compared to baseline and without any other intervention (medication or secondary surgery) (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-09
Completion: 2026-12
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: false
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nova Eye, Inc.
Collaborators: Nova Eye Medical GmbH
Principal Investigators:
  • Shamil Patel, MD, MBA (PRINCIPAL_INVESTIGATOR) - Eye Physicians and Surgeons of Arizona
Contact Information
Study Contact:
Mike Pickrel
1-800-391-2316
mpickrel@nova-eye.com
Karsten Klabe, MD
Breyer Kaymak Klabe Augenchirurgie
Jose Martinez de la Casa, MD
Hospital Clinico San Carlos, Servicio de Oftalmologia
Interventions
  • Device: Ab-interno canaloplasty utilizing the iTrack Advance device — 360 degree microcatheterization and viscodilation of Schlemm's canal
  • Device: Ab-interno canaloplasty utilizing the OMNI Surgical System — 360 degree microcatheterization and viscodilation of Schlemm's canal
Study Locations (5 sites)
Breyer Kaymak Klabe Augenchirurgie, Düsseldorf, Germany
Hospital Clinico San Carlos, Servicio de Oftalmologia, Madrid, Spain
Princess Alexandra Eye Pavilion, NHS Lothian, Edinburgh, United Kingdom
St. Paul's Eye Unit, Liverpool University, Liverpool, United Kingdom
Manchester Royal Eye Hospital, Manchester, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Male or female subjects, 22 years or older at the time of surgery * Diagnosed with mild to moderate primary open angle glaucoma * Candidate for canaloplasty surgery: i.e., catheterization of Schlemm's canal and subsequent viscodilation of Schlemm's canal, without trabeculotomy * Intolerance to medical therapy OR need/willingness to reduce medications * At the Screening Visit, IOP of ≤ 30 mmHg while on 1-4 ocular hypotensive medications * At the Baseline Visit, unmedicated IOP ≥ 21mmHg and ≤ 36 mmHg, and ≥ 3mmHg higher than medicated IOP * Shaffer grade of ≥ 3 in all four quadrants * Central corneal thickness ≥ 480µm and ≤ 620 µm * Able and willing to comply with the study procedures and attend all follow-up visits * Understands and signs the informed consent Exclusion Criteria: * Any of the following prior treatments for glaucoma (study eye): 1. Laser trabeculoplasty i. Selective Laser Trabeculoplasty (SLT) conducted within 6-months of the Screening Visit ii. Prior Argon Laser Trabeculoplasty 2. iStent or iStent Inject within 180 days of the Screening Visit 3. Endocyclophotocoagulation (ECP) or Micropulse laser 4. Trabeculectomy or other bleb forming procedure including Xen, Express, and glaucoma draining device/valve 5. Prior canaloplasty (ab interno and ab externo) 6. Prior goniotomy, or trabeculotomy (ab externo and ab interno) 7. Hydrus microstent 8. Suprachoroidal stent (e.g., Cypass, iStent Supra, MINIject) 9. Concurrent IOP-lowering procedure other than use of the iTrack Advance canaloplasty device OR the OMNI Surgical System at the time of surgery (e.g., ECP, CPC, etc.) * Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma, pigmentary glaucoma or pseudoexfoliative glaucoma * Cataract surgery within 6 months of the Screening Visit in the study eye * History of fellow eye with cataract surgery within 30 days of Screening * Subjects at significant risk by a washout of ocular hypotensive medication, and/or subjects where the unmedicated IOP is expected to exceed the upper limit of 36 mmHg * Use of systemic medications (either current, within 30 calendar days of Screening exam, or anticipated) that may cause an increase in IOP, (e.g., systemic steroids including inhaled and oral steroids used on a regular basis) * Ocular and/or systemic diseases that could affect the corneal endothelium (such as corneal endothelial dystrophy, intraocular inflammation and infection, or congenital abnormalities) * History of penetrating keratoplasty or another corneal transplant * BCVA of 20/200 or worse in the fellow eye not due to cataract * Previous treatment with OMNI or iTrack (Note: permitted if fellow eye only was treated) * BCVA of 20/50 or worse in the study eye not due to posterior capsular opacification
Conditions Heart Failure With Reduced Ejection Frac...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the feasibility and diagnostic accuracy of the CART-BP ring-type wearable blood pressure monitoring device in comparison with 24-hour ambulatory blood pressure monitoring (ABPM) in patients with heart failure with reduced ejection fraction (HFrEF, LVEF ≤ 40%). As a multi-center, prospective, exploratory study, 100 patients will be enrolled at two tertiary hospitals in South Korea. The agreement between the two devices in 24-hour mean, daytime, and nighttime blood pressure measurements will be assessed per ISO 81060-2:2018 criteria.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Agreement between CART-BP and ABPM in 24-hour mean systolic and diastolic blood pressure (24 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-23
Completion: 2026-10-22
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Keimyung University Dongsan Medical Center
Contact Information
Study Contact:
In-Cheol Kim
82-53-258-4629
kimic@dsmc.or.kr
Hyemin Kwon
82-53-258-6691
irbdsmc@naver.com
Keimyung University Dongsan Medical Center
Interventions
N/A
Study Locations (1 sites)
Keimyung University Dongsan Medical Center, Daegu, 42601 South Korea
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 19 years (male or female) 2. Diagnosed with heart failure and currently under treatment 3. Left ventricular ejection fraction (LVEF) ≤ 40% confirmed by echocardiography performed within 1 year prior to enrollment 4. Able to undergo both 24-hour ambulatory blood pressure monitoring and ring-type blood pressure measurement 5. Voluntarily provided written informed consent to participate in this clinical study Exclusion Criteria: 1. Office blood pressure: SBP \< 90 mmHg, or DBP \< 50 mmHg, or SBP \> 180 mmHg, or DBP \> 100 mmHg 2. Unable to perform 24-hour ambulatory blood pressure monitoring 3. Unable to wear or use the ring-type blood pressure device 4. Variability in three consecutive resting cuff blood pressure measurements ≥ 20 mmHg (SBP) or ≥ 10 mmHg (DBP) 5. Insufficient valid ABPM readings: \< 25 daytime or \< 12 nighttime measurements per ESH criteria; or \< 25 daytime or \< 12 nighttime valid readings from the ring-type device 6. Pregnant, suspected pregnancy, or breastfeeding 7. Judged by the investigator to be legally or mentally unfit to participate in the clinical study
Conditions Hypertension (HTN)
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Renal denervation (RDN) is a recent procedure that can be used to control BP (blood pressure) in hypertensive patients. Numerous publications from randomised trials have demonstrated the efficacy of RDN in this indication. The latest guidelines now include RDN as an effective technique for use in hypertension. Since early 2023, RDN using Medtronic's Spiral radiofrequency system has benefited from transitional authorisation for reimbursement by the French health insurance system. An application for reimbursement is underway for the ultrasound system. We aim to compile an exhaustive prospective register of all procedures carried out in France over the next few years, regardless of the type of catheter used or the context in which the procedure was carried out (transitional reimbursement, industrial register, randomised trial). Our aim is to assess the efficacy and safety of the procedure within the French healthcare system, the characteristics of patients benefiting from the procedure, the centres performing renal denervation, and the care pathways used, and to be able to present all this data, independently of the industry, to the healthcare authorities when it comes time to reassess the value of this procedure and its indications. The goal of this observational study is to learn about changes in blood pressure in patient with high blood pressure before and 1 year after a renal denervation treatment (RDN). The primary endpoint is to describe changes in systolic blood pressure (SBP) measured by Home Blood Pressure Measurement (HBPM) in patients suffering from high blood pressure, before and 1 year after RDN.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • Change in SBP measured by HBPM before and after RDN (1 year). (before intervention and 1 year after intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-23
Completion: 2028-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Grenoble
Principal Investigators:
  • Olivier ORMEZZANO, Doctor of medicine (PRINCIPAL_INVESTIGATOR) - University Hospital, Grenoble
Contact Information
Study Contact:
Olivier ORMEZZANO, Doctor of medicine
+33476768888
oormezzano@chu-grenoble.fr
Olivier pollet, Master
+33476768823
dpollet@chu-grenoble.fr
Olivier ORMEZZANO, Doctor of medicine
+33476768888
oormezzano@chu-grenoble.fr
Chu Grenoble Alpes
Interventions
N/A
Study Locations (1 sites)
Chu Grenoble Alpes, La Tronche, France 38700 France
Eligibility Criteria
Inclusion Criteria: * Adult ( \> 18 years old) hypertensive patients treated with RDN in France whatever the catheter and the indication. This might include retrospective data for patient already treated with RDN in the past. Exclusion Criteria: * RDN not proposed to the patient, patient opposing the collection and use of his/her data for research purposes.
Conditions Diabetes Mellitus, Type 2, Obesity, Hype...
Phase NA
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This project will determine whether a diet culturally adapted to adults in Puerto Rico can effectively decrease cardiometabolic risk factors. This will help define a culturally-appropriate, feasible, and sustainable diet intervention aimed at reducing cardiovascular, type 2 diabetes, and obesity outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Culturally tailored food and diet advice — Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
  • Behavioral: Standard healthy eating advice — Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate For A Healthy Puerto Rico dietary recommendations.

Primary Outcomes

  • 10-year risk score for a first atherosclerotic CVD event (ASCVD score) (6; 12; 18; 24 months)
  • Cardiometabolic Improvement Score (CIS) (6; 12; 18; 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-02
Completion: 2029-05-02
Eligibility
Age: 30 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Harvard School of Public Health (HSPH)
Collaborators: Yale University, Broad Institute of MIT and Harvard, Puerto Rico Consortium for Clinical Investigations
Principal Investigators:
  • Josiemer Mattei, PhD, MPH (PRINCIPAL_INVESTIGATOR) - Harvard Chan School of Public Health
  • Amarilys F Sylva, PhD (STUDY_DIRECTOR) - Puerto Rico Consortium for Clinical Investigations
Contact Information
Study Contact:
Natalia Torres, BS
787-523-1593
natalia.torres@prcci.org
Natalia Torres, BS
787-523-1593
natalia.torres@prcci.org
Puerto Rico Consortium for Clinical Investigation
Amarilys F Sylva, PhD
Puerto Rico Consortium for Clinical Investigation
Interventions
  • Behavioral: Culturally tailored food and diet advice — Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
  • Behavioral: Standard healthy eating advice — Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate For A Healthy Puerto Rico dietary recommendations.
Study Locations (1 sites)
Puerto Rico Consortium for Clinical Investigation, San Juan, 00926 Puerto Rico
Eligibility Criteria
Inclusion Criteria: 1. Age 30-65y old at the time of enrollment 2. Non-institutionalized 3. Living in PR at the time of recruitment and for at least the previous year and not planning to move from the island within the next 3 years 4. Able to answer questions without assistance 5. Having a cellphone with the capacity to receive text messages and be willing to receive daily text messages from the study on the designated cellphone number 6. Having at least one of the following: 1. elevated BMI 2. elevated waist circumference 3. self-reported physician-diagnosed hypertension or use of hypertension medication or measured high blood pressure at the baseline visit 4. self-reported physician-diagnosed pre-diabetes or measured pre-diabetes at the baseline visit 5. self-reported physician-diagnosed dyslipidemia or use of lipid-lowering agents or laboratory values confirming dyslipidemia Exclusion Criteria: 1. Under 30 or over 65 years of age (on the day of the interview). 2. Currently not living in Puerto Rico or not lived on the island for at least 1 year or planning to move within 3 years 3. Institutionalized 4. Not able to answer questions without assistance 5. Not having at least 1 of the five listed metabolic criteria 6. Self-reported physician-diagnosed type 1 or type 2 diabetes or use of diabetes medication (including insulin) or diabetes-diagnosis values confirmed by laboratory 7. Self-reported pregnancy 8. Gastrointestinal or chronic condition that would impact eating behaviors or nutritional status 9. Intolerance or allergies to legumes (i.e.: beans and nuts), vegetable oils (i.e.: corn, olive, canola), or fresh produce 10. Living with another person participating in the study 11. Participating in another research study that conflicts with PRECISION
Conditions Hypertension
Phase Not Applicable
Enrollment 500
Locations 26 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this registry (NCT02880631) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: BAROSTIM NEO™ System

Primary Outcomes

  • Blood Pressure Changes (Pre-implant baseline to 3 years post-implant)
  • Cardiovascular Medication Changes (Post-implant enrollment to 3 years post-implant)
  • Number of Health Care Utilizations (3 months post-implant to 3 years post-implant)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2016-12-13
Completion: 2027-07
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CVRx, Inc.
Principal Investigators:
  • Hannes Reuter, PhD (STUDY_CHAIR) - Herzzentrum Uniklinik Köln
Contact Information
Study Contact:
Nicole Baumann
763-416-2331
nbaumann@cvrx.com
Daniela Bettin
+49 333 869 4604
d.bettin@immanuel.de
Immanuel Klinikum Bernau Herzzentrum Brandenburg
Christian Butter
Immanuel Klinikum Bernau Herzzentrum Brandenburg
Interventions
  • Device: BAROSTIM NEO™ System
Study Locations (26 sites)
Charité Benjamin Franklin, Berlin, 12203 Germany
Charité Campus Virchow, Berlin, 13353 Germany
Immanuel Klinikum Bernau Herzzentrum Brandenburg, Bernau, 16321 Germany
Cloppenburg Katholische Kliniken Münsterland, Cloppenburg, 49661 Germany
Universitätsklinikum Köln Herzzentrum, Cologne, 50937 Germany
Lippe Klinikum, Detmold, 32756 Germany
Herzzentrum Dresden, Dresden, 01307 Germany
Krankenhaus Erding, Erding, 85435 Germany
Cardiovascular Center 'CVC' Frankfurt, Frankfurt, 60398 Germany
Universitätsklinikum Gießen und Marburg, Giessen, 35392 Germany
Eligibility Criteria
Inclusion Criteria: * Has signed an EC approved informed consent form * Has been implanted with the BAROSTIM NEO system in the past 30 days * Systolic blood pressure greater than or equal to 140 mmHg, and * Resistance to maximally tolerated therapy with a diuretic and two other anti-hypertension medications Exclusion Criteria: * Bilateral carotid bifurcations located above the level of the mandible * Baroreflex failure or autonomic neuropathy * Uncontrolled, symptomatic cardiac bradyarrhythmias * Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50% * Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation
Conditions Gall Bladder Cancer, Intrahepatic Cholan...
Phase Not Applicable
Enrollment 1800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Biliary tract carcinoma (BTC), including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma, ranks sixth in incidence among gastrointestinal malignancies and tenth in cancer-related mortality worldwide. Due to the lack of specific early symptoms, high malignancy, and frequent recurrence and metastasis, the rate of curative resection is only about 16.5%, and the overall 5-year survival rate is less than 5%. Early and accurate detection is therefore critical for improving patient outcomes. Circulating tumor DNA (ctDNA), a fraction of circulating free DNA (cfDNA), carries genetic and epigenetic information from tumor cells and can be detected even at the early stages of cancer development. Among various liquid biopsy biomarkers, ctDNA methylation shows particular advantages in sensitivity and specificity for early cancer detection and monitoring. This study aims to evaluate the application of cfDNA methylation liquid biopsy in the diagnosis and management of BTC.

Design

Study type: Observational Observational model: Case Control Time perspective: Other

Primary Outcomes

  • Diagnostic performance of the ctDNA methylation model in biliary tract cancer (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-01-01
Completion: 2026-05-01
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 1800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yingbin Liu, MD, PhD, FACS
Collaborators: Qilu Hospital of Shandong University, Xijing Hospital, First Affiliated Hospital Xi'an Jiaotong University, West China Hospital, Sun Yat-Sen University Cancer Center, Hunan Provincial People's Hospital, Fudan University
Principal Investigators:
  • Yingbin Liu, PhD (PRINCIPAL_INVESTIGATOR) - RenJi Hospital
Contact Information
Study Contact:
Yingbin Liu, PhD
+86 13918803900
laoniulyb@163.com
Yingbin Liu, PhD
+86 13918803900
laoniulyb@163.com
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Interventions
N/A
Study Locations (1 sites)
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, Shanghai Municipality 200127 China
Eligibility Criteria
Inclusion Criteria Internal Training and Validation Cohorts * BTC patients 1. Willing to voluntarily participate and able to comply with study procedures; if unable to read or sign, informed consent must be signed by a legally authorized representative (LAR). 2. Age 18-80 years (inclusive). 3. Able to provide required blood samples. 4. Pathologically confirmed biliary tract carcinoma (TNM stage I-IV). 5. Stable vital signs; ECOG performance status 0-1. 6. Adequate organ function: AST/ALT ≤ 5 × ULN; Child-Pugh class A or B; WBC \> 3 × 10⁹/L; ANC ≥ 1.5 × 10⁹/L; Platelets ≥ 75 × 10⁹/L; Hemoglobin ≥ 90 g/L; Creatinine clearance ≥ 60 mL/min; Total bilirubin ≤ 3 × ULN. * Other gastrointestinal malignancies (to exclude BTC non-specific signals) 1. Voluntary participation with signed informed consent (or by LAR). 2. Age 18-80 years (inclusive). 3. Able to provide required blood samples. 4. Pathologically confirmed gastrointestinal malignancies other than BTC, including hepatocellular carcinoma, gastric cancer, colorectal cancer, and pancreatic cancer (TNM stage I-IV). 5. Stable vital signs; ECOG performance status 0-1. * Non-cancer participants (benign biliary disease) 1. Able to provide written informed consent. 2. Able to provide required blood samples. 3. Age 18-80 years (inclusive). 4. Pathologically or clinically diagnosed benign biliary diseases, including cholecystitis, cholelithiasis, choledocholithiasis, adenomyomatosis, gallbladder polyps, xanthogranulomatous cholecystitis, or primary sclerosing cholangitis. External Validation Cohorts * BTC patients 1. Voluntary participation with signed informed consent (or by LAR). 2. Imaging findings of malignant biliary stricture or mass, or serum CA19-9 \> 100 U/mL, highly suspicious for BTC, with planned surgery or biopsy for pathological confirmation. 3. Age 18-80 years (inclusive). 4. Able to provide required blood samples. 5. Stable vital signs; ECOG performance status 0-1. 6. Adequate organ function: AST/ALT ≤ 5 × ULN; Child-Pugh class A or B; WBC \> 3 × 10⁹/L; ANC ≥ 1.5 × 10⁹/L; Platelets ≥ 75 × 10⁹/L; Hemoglobin ≥ 90 g/L; Creatinine clearance ≥ 60 mL/min; Total bilirubin ≤ 3 × ULN. * Healthy volunteers 1. Able to provide written informed consent. 2. Able to provide required blood samples. 3. Age 18-80 years (inclusive). Exclusion Criteria Training and Validation Cohorts * Cancer patients 1. Pregnant or breastfeeding women. 2. History of organ transplantation or prior allogeneic bone marrow/stem cell transplantation. 3. Blood transfusion within 7 days prior to blood collection. 4. History of curative cancer treatment within 3 years prior to blood collection. 5. Use of anti-tumor drugs within 30 days prior to blood collection. 6. Known bleeding disorders. 7. Known autoimmune diseases. 8. Concurrent other malignancies or multiple primary tumors. * Non-cancer participants 1. Pregnant or breastfeeding women. 2. History of organ transplantation or prior allogeneic bone marrow/stem cell transplantation. 3. Blood transfusion within 7 days prior to blood collection. 4. History of any malignant tumor. 5. Known bleeding disorders. 6. Known autoimmune diseases. 7. Clinically significant abnormalities on routine examination (excluding hepatitis, hepatic cysts, or benign pulmonary nodules). External Validation Cohorts * Cancer patients 1. Pregnant or breastfeeding women. 2. History of organ transplantation or prior allogeneic bone marrow/stem cell transplantation. 3. Blood transfusion within 7 days prior to blood collection. 4. History of or ongoing curative cancer treatment within 3 years prior to blood collection. 5. Use of anti-tumor drugs within 30 days prior to blood collection. 6. Known bleeding disorders or autoimmune diseases. 7. Concurrent other malignancies (including multiple primaries) or known cancer susceptibility gene carriers. 8. Pathology confirmed benign disease after biopsy/surgery. 9. Failure to confirm malignancy by pathology or imaging within 42 days after blood collection, or unclear lesion site/evidence. 10. Special exclusion criteria: * Pathology confirmed precancerous lesions. * Any local/regional or systemic anti-tumor therapy (including surgery, radiotherapy, targeted therapy, or immunotherapy) prior to blood collection. * Healthy volunteers 1. Pregnant or breastfeeding women. 2. History of organ transplantation or prior allogeneic bone marrow/stem cell transplantation. 3. Blood transfusion within 7 days prior to blood collection. 4. History of any malignant tumor. 5. Known bleeding disorders or autoimmune diseases. 6. Clinically significant abnormalities on health examination (excluding hepatitis, hepatic cysts, or benign pulmonary nodules).
Conditions Clear Cell Renal Cell Cancer (ccRCC), Ur...
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: 18F-T2 PET/CT — 18F-T2 is injected intravenously with a dose of 0.05-0.10 mCi/kg. The CT and PET imaging session will begin approximately 60 minutes after 18F-T2 administration.

Primary Outcomes

  • The Diagnostic Sensitivity and Specificity of 18F-T2 PET/CT in the Evaluation of CAIX Positive Solid Tumors (From study completion to 1 month after completion)
  • Incidence of Adverse Events [Safety and Tolerability] (24 hours after the injection of 18F-T2)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-27
Completion: 2029-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University First Hospital
Principal Investigators:
  • Meng Liu (PRINCIPAL_INVESTIGATOR) - Peking University First Hospital
Contact Information
Study Contact:
Keting Tong
+86 010-83575252
1910301229@pku.edu.cn
Peking University First Hospital
+86 010-83576401
bdyyll@126.com
Peking University First Hospital
Interventions
  • Diagnostic Test: 18F-T2 PET/CT — 18F-T2 is injected intravenously with a dose of 0.05-0.10 mCi/kg. The CT and PET imaging session will begin approximately 60 minutes after 18F-T2 administration.
Study Locations (1 sites)
Peking University First Hospital, Beijing, Beijing Municipality 100034 China
Eligibility Criteria
Inclusion Criteria: All participants must meet the following criteria: 1. Written and voluntarily given Informed Consent. 2. Male or female ≥18 years of age at time of consent. 3. Have the capacity to understand the study and be willing and able to comply with all protocol requirements. 4. Participants with histologically confirmed or suspected tumors of the following types, but not limited to: Clear Cell Renal Cell Cancer; Urothelial Carcinoma; Colorectal Cancer; Cervical Cancer; Ovarian Cancer; Head and Neck Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Non Small Cell Lung Cancer; Small Cell Lung Cancer; Breast Cancer; Pancreatic Cancer; Endometrial Cancer; Von Hippel Lindau Disease. Exclusion Criteria: Participants will be excluded from participation in the study if one or more of the following criteria are met: 1. Have any serious non-malignant disease (e.g., psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the participant, as judged by the Investigator. 2. Have a mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study. 3. Be a female who is pregnant or breastfeeding.